Liminatus Pharma, Inc. (NASDAQ: LIMN) announced that it will launch a Phase 1 clinical trial of its lead candidate IBA101, a next‑generation monoclonal antibody that blocks the CD47 “don’t‑eat‑me” signal and is designed to work in concert with PD‑1/PD‑L1 checkpoint inhibitors.
The trial will begin with a monotherapy dose‑escalation cohort to assess safety, tolerability and pharmacokinetics, followed by combination cohorts that pair IBA101 with approved PD‑1/PD‑L1 agents. Lung cancer has been selected as the initial indication because of the widespread use of checkpoint inhibitors in this disease and the opportunity to improve depth and durability of response.
Regulatory filings for the trial are slated for the second half of 2026, with site activations and patient screening expected in early 2027. The company’s development plan therefore reflects a multi‑year timeline from announcement to first patient enrollment, underscoring that the trial is not imminent but a near‑future milestone.
Liminatus’s financial profile is fragile: its market capitalization is roughly $9.3 million, and the company has lost 97.7 % of its value over the past year. Cash flow is negative, the current ratio is low, debt‑to‑equity is negative, and the Altman Z‑score is 0, indicating a high bankruptcy risk. These metrics highlight the substantial capital requirements and risk exposure that accompany the progression of a pre‑clinical candidate to human trials.
CD47‑blocking antibodies have historically faced safety challenges, notably anemia and thrombocytopenia, which limited earlier candidates. IBA101 is engineered as a second‑generation antibody that selectively targets CD47 epitopes on tumor and immune cells while sparing red blood cells and platelets, a design intended to mitigate the adverse events that plagued its predecessors.
Management has emphasized the company’s mission to develop immunotherapies that restore immune balance and deliver safer, more durable anti‑tumor responses. CEO Chris Kim has underscored that Liminatus’s core objective is to advance transformative immunotherapies for cancer, positioning IBA101 as a potential breakthrough in the CD47 space.
The announcement marks a pivotal transition from pre‑clinical to clinical development, but the extended timeline and financial constraints temper expectations. If IBA101 demonstrates safety and early efficacy, it could validate the CD47 target and open a new therapeutic avenue, especially when combined with PD‑1/PD‑L1 inhibitors. Conversely, the company’s limited resources and the historical safety record of CD47 agents represent significant headwinds that could delay or derail the program. Investors and stakeholders will closely monitor regulatory submissions, site activation progress, and early safety data to gauge the viability of this ambitious strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.